Emerald Health Therapeutics’ Pure Sunfarms JV Reaches Q2 Sales of $32 Million, 78% EBITDA Margin, $0.65/Gram All-in Production Cost, and Third Consecutive Quarter of Profitability

Emerald Health Therapeutics’ Pure Sunfarms JV Reaches Q2 Sales of $32 Million, 78% EBITDA Margin, $0.65/Gram All-in Production Cost, and Third Consecutive Quarter of Profitability Emerald Health Therapeutics to report second quarter 2019 financial results on August...